XML 110 R81.htm IDEA: XBRL DOCUMENT v3.22.1
Assets and liabilities from subsidiaries held for sale and discontinued operations (Details 2) - BRL (R$)
R$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Assets and liabilities from subsidiaries held for sale and discontinued operations      
Net revenue from sales and services R$ 109,732,842 R$ 74,058,056 [1] R$ 83,004,729 [1]
Cost of products and services sold (104,827,966) (70,056,447) (78,208,786)
Gross profit 4,904,876 4,001,609 4,795,943
Operating income (expenses)      
Selling marketing and administrative (1,934,789) (1,595,871) (1,631,760)
Other operating income, net 96,166 64,034 140,029
Operating income (loss) before finance income (expenses) and share of profit (loss) of joint ventures and associates 1,787,014 1,545,960 2,051,237
Share of profit of associates 434 1,781 1,754
Operating income before finance income (expenses) and income and social contribution taxes 1,769,380 1,501,929 2,038,528
Financial result, net (762,732) (550,348) [2] (673,351) [2]
Profit (loss) before income and social contribution taxes 1,006,648 951,581 1,365,177
Profit (loss) for the year 65,264 280,633 (492,257)
Depreciation and amortization for the year 1,196,355 1,127,637 [3] 1,123,627
Net cash provided by (used in) operating activities 982,519 874,106 552,468
Net cash used in investing activities (158,733) (487,390) (995,923)
Net cash provided by (used in) financing activities (552,967) (919,684) (241,907)
Effect of exchange rate changes on cash and cash equivalents in foreign currency 56,553 114,822 30,871
Extrafarma [member]      
Operating income (expenses)      
Impairment (427,529)    
Eliminations      
Assets and liabilities from subsidiaries held for sale and discontinued operations      
Net revenue from sales and services (214,715) (193,046) (127,397)
Cost of products and services sold 194,118 133,384 119,405
Gross profit (20,597) (59,662) (7,992)
Operating income (expenses)      
Selling marketing and administrative
Other operating income, net
Operating income (loss) before finance income (expenses) and share of profit (loss) of joint ventures and associates
Operating income before finance income (expenses) and income and social contribution taxes
Depreciation and amortization for the year
Total Discontinued operations      
Assets and liabilities from subsidiaries held for sale and discontinued operations      
Net revenue from sales and services 9,065,795 7,183,046 (6,293,246)
Cost of products and services sold (6,901,181) (5,571,767) (4,978,323)
Gross profit 2,164,614 1,611,279 1,314,923
Operating income (expenses)      
Selling marketing and administrative (1,664,015)    
Impairment (427,529)    
Other operating income, net 25,815    
Operating income (loss) before finance income (expenses) and share of profit (loss) of joint ventures and associates 98,885 266,095 (750,685)
Share of profit of associates 48    
Operating income before finance income (expenses) and income and social contribution taxes 98,933 266,509 (750,121)
Financial result, net (146,970) 280,974 166,497
Profit (loss) before income and social contribution taxes (48,037) 547,483 (583,624)
Income and social contribution taxes 113,301    
Profit (loss) for the year 65,264 280,633 492,257
Depreciation and amortization for the year 463,414 [4] 428,962 [3] 376,328
Net cash provided by (used in) operating activities 982,519    
Net cash used in investing activities (158,733)    
Net cash provided by (used in) financing activities (552,967)    
Effect of exchange rate changes on cash and cash equivalents in foreign currency 56,553    
(Decrease) increase in cash and cash equivalents 327,372    
Total Discontinued operations | Oxiteno S. A. Industria e Comercio [member]      
Assets and liabilities from subsidiaries held for sale and discontinued operations      
Net revenue from sales and services 7,102,771 5,210,704 4,254,237
Cost of products and services sold (5,540,773) (4,188,711) (3,537,570)
Gross profit 1,561,998 1,021,993 716,667
Operating income (expenses)      
Selling marketing and administrative (978,221)    
Impairment 0    
Other operating income, net 26,924    
Operating income (loss) before finance income (expenses) and share of profit (loss) of joint ventures and associates 610,701 344,394 (26,287)
Share of profit of associates 48    
Operating income before finance income (expenses) and income and social contribution taxes 610,749 344,808 (25,759)
Financial result, net (431,441) 1,482 14,464
Profit (loss) before income and social contribution taxes 179,308 346,290 (11,295)
Income and social contribution taxes 69,995    
Profit (loss) for the year 249,303 0 (23,896)
Depreciation and amortization for the year 308,564 [4] 275,063 [3] (222,004)
Net cash provided by (used in) operating activities 1,016,580    
Net cash used in investing activities (122,363)    
Net cash provided by (used in) financing activities (1,054,930)    
Effect of exchange rate changes on cash and cash equivalents in foreign currency 56,553    
(Decrease) increase in cash and cash equivalents (104,160)    
Total Discontinued operations | Extrafarma [member]      
Assets and liabilities from subsidiaries held for sale and discontinued operations      
Net revenue from sales and services 1,986,932 1,988,411 2,060,569
Cost of products and services sold (1,384,316) (1,399,125) (1,462,313)
Gross profit 602,616 589,286 598,256
Operating income (expenses)      
Selling marketing and administrative (685,794)    
Impairment (427,529)    
Other operating income, net (1,109)    
Operating income (loss) before finance income (expenses) and share of profit (loss) of joint ventures and associates (511,816) (78,299) (724,398)
Share of profit of associates 0    
Operating income before finance income (expenses) and income and social contribution taxes (511,816) (78,299) (724,398)
Financial result, net (45,265) (38,938) (32,451)
Profit (loss) before income and social contribution taxes (557,081) (117,237) (756,849)
Income and social contribution taxes 155,416    
Profit (loss) for the year (401,665) 0 637,948
Depreciation and amortization for the year 154,850 [4] 153,899 [3] (154,324)
Net cash provided by (used in) operating activities (33,273)    
Net cash used in investing activities (35,072)    
Net cash provided by (used in) financing activities 35,286    
Effect of exchange rate changes on cash and cash equivalents in foreign currency 0    
(Decrease) increase in cash and cash equivalents (33,059)    
Total Discontinued operations | Eliminations      
Assets and liabilities from subsidiaries held for sale and discontinued operations      
Net revenue from sales and services (23,908) [5] (16,069) (21,560)
Cost of products and services sold 23,908 [5] 16,069 21,560
Gross profit 0 [5] 0 0
Operating income (expenses)      
Selling marketing and administrative [5] 0    
Impairment [5] 0    
Other operating income, net [5] 0    
Operating income (loss) before finance income (expenses) and share of profit (loss) of joint ventures and associates 0 [5] 0 0
Share of profit of associates [5] 0    
Operating income before finance income (expenses) and income and social contribution taxes 0 [5] 0 36
Financial result, net 329,736 [5] 318,430 (184,484)
Profit (loss) before income and social contribution taxes 329,736 [5] 318,430 184,520
Income and social contribution taxes [5] (112,110)    
Profit (loss) for the year 217,626 [5] 0 (121,795)
Depreciation and amortization for the year 0 [4],[5] R$ 0 [3] R$ 0
Net cash provided by (used in) operating activities (788)    
Net cash used in investing activities (1,298)    
Net cash provided by (used in) financing activities 466,677    
Effect of exchange rate changes on cash and cash equivalents in foreign currency 0    
(Decrease) increase in cash and cash equivalents R$ 464,591    
[1] For further information see Note 3.c.3.
[2] For further details, see Note 3.c.3.
[3] Balances included for complete breakdown of segment information.
[4] Balances included for complete breakdown of segment information.
[5] Elimination between continuing and discontinued operations related to the intercompany loan (PPE) between Ultrapar International and Oxiteno.